{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T02:17:13Z","timestamp":1784945833451,"version":"3.55.0"},"reference-count":23,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T00:00:00Z","timestamp":1491523200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychogeriatrics"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The simultaneous use of dementia medications and anticholinergic medications occurs frequently. Cholinesterase inhibitors and anticholinergic medications likely counteract one another, potentially exposing patients to medications with decreased benefit, more adverse effects, and higher cost of care. We identified the rate of concurrent prescriptions of cholinesterase inhibitors\/memantine with anticholinergics in an urban hospital setting with a large <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>sian and <jats:styled-content style=\"fixed-case\">P<\/jats:styled-content>acific <jats:styled-content style=\"fixed-case\">I<\/jats:styled-content>slander population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study is a retrospective review of patients hospitalized from 1 <jats:styled-content style=\"fixed-case\">J<\/jats:styled-content>anuary 2006 to 31 <jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>ecember 2010 at a general hospital who simultaneously received US <jats:styled-content style=\"fixed-case\">Food and Drug Administration<\/jats:styled-content>\u2010approved dementia medications (galantamine, rivastigmine, donepezil, and\/or memantine) and anticholinergics.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 304 patients receiving cholinesterase inhibitors\/memantine also received anticholinergics. Of these patients, 64.1% were given high\u2010potency anticholinergic medications, and 35.9% received medium\u2010potency medications. Indications for the use of anticholinergic medication were urological (17.8%), gastrointestinal excluding nausea (32.6%), nausea (10.2%), psychiatric (7.9%), and other (31.6%). Asian patients received the combination of cholinesterase inhibitors\/memantine and anticholinergics less frequently than <jats:styled-content style=\"fixed-case\">N<\/jats:styled-content>ative <jats:styled-content style=\"fixed-case\">H<\/jats:styled-content>awaiian or <jats:styled-content style=\"fixed-case\">C<\/jats:styled-content>aucasian patients (8.4% vs 12.2% and 13.3%, respectively; \u03c7<jats:sup>2<\/jats:sup>\u2009=\u200916.04, degrees of freedom\u2009=\u20092, <jats:italic>P<\/jats:italic>\u2009&lt; 0.0003).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Simultaneous prescribing of cholinesterase inhibitors, memantine, and anticholinergic medications was significantly less common than in previous studies, with some ethnic variability. The less frequent occurrence of concurrent medications in the <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>sian population may be because of variations in the rate of indications or in tolerability for anticholinergic medications among the population.<\/jats:p><\/jats:sec>","DOI":"10.1111\/psyg.12267","type":"journal-article","created":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T06:18:40Z","timestamp":1491545920000},"page":"423-429","source":"Crossref","is-referenced-by-count":5,"title":["Simultaneous usage of dementia medications and anticholinergics among <scp>A<\/scp>sians and <scp>P<\/scp>acific <scp>I<\/scp>slanders"],"prefix":"10.1111","volume":"17","author":[{"given":"Brian R.","family":"Schultz","sequence":"first","affiliation":[{"name":"Department of Psychiatry, John A. Burns School of Medicine University of Hawaii  Honolulu Hawaii USA"},{"name":"The Queen's Medical Center  Honolulu Hawaii USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Takeshita","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, John A. Burns School of Medicine University of Hawaii  Honolulu Hawaii USA"},{"name":"The Queen's Medical Center  Honolulu Hawaii USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Goebert","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, John A. Burns School of Medicine University of Hawaii  Honolulu Hawaii USA"},{"name":"The Queen's Medical Center  Honolulu Hawaii USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Takeshita","sequence":"additional","affiliation":[{"name":"Princeton University  Princeton New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett Y.","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, John A. Burns School of Medicine University of Hawaii  Honolulu Hawaii USA"},{"name":"The Queen's Medical Center  Honolulu Hawaii USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Guilloux","sequence":"additional","affiliation":[{"name":"The Queen's Medical Center  Honolulu Hawaii USA"},{"name":"Department of Cell and Molecular Biology University of Hawaii  Honolulu Hawaii USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Higa","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, John A. Burns School of Medicine University of Hawaii  Honolulu Hawaii USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,4,7]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"1365","article-title":"Pharmacologic treatment of Alzheimer's disease: an update","volume":"68","author":"DeLaGarza VW","year":"2003","journal-title":"Am Fam Physician"},{"key":"e_1_2_6_3_1","first-page":"64","article-title":"Treatment disparities in medication prescribing for Alzheimer's: disease among ethnic groups","volume":"35","author":"Perryman M","year":"2009","journal-title":"J Health Care Finance"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.7.808"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2004.52563.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200825100-00006"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.2005.25.12.1729"},{"key":"e_1_2_6_8_1","first-page":"219","volume-title":"Goodman & Gilman's The Pharmacological Basis of Therapeutics","author":"Brown JH","year":"2011"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2008.01681.x"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2009.02258.x"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2011.03654.x"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2010-1269"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/JGP.0b013e3181bf9caf"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270006292126"},{"key":"e_1_2_6_15_1","unstructured":"Clinical Pharmacology(online database). Tampa FL: Gold Standard Inc.;2016. [Accessed November 2016] Available from URL:http:\/\/www.clinicalpharmacology.com. Updated Aug 2013 (meperidine); Sep 2013 (promethazine tolterodine); April 2014 (oxcarbazepine); May 2014 (ranitidine); Nov 2014 (oxybutynin); June 2015 (benztropine); July 2015 (diphenhydramine); Aug 2015 (nortriptyline); June 2016 (meclizine); Nov 2016 (hydroxyzine)."},{"key":"e_1_2_6_16_1","unstructured":"Natural Medicines(online database). Somerville MA: Therapeutic Research Center;2015. [Cited Nov 2016.] Available from URL:http:\/\/naturalmedicines.therapeuticresearch.com"},{"key":"e_1_2_6_17_1","first-page":"1042","article-title":"The use of medications with known or potential anticholinergic activity in patients with dementia receiving cholinesterase inhibitors","volume":"18","author":"Mann JL","year":"2003","journal-title":"Consult Pharm"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afn197"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04396.x"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2009.11.021"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)00039-X"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2011.09.010"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270004268128"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.274"}],"container-title":["Psychogeriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpsyg.12267","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/psyg.12267","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T12:39:46Z","timestamp":1695559186000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/psyg.12267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,7]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1111\/psyg.12267"],"URL":"https:\/\/doi.org\/10.1111\/psyg.12267","archive":["Portico"],"relation":{},"ISSN":["1346-3500","1479-8301"],"issn-type":[{"value":"1346-3500","type":"print"},{"value":"1479-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,7]]}}}